LigaChem Biosciences

1.1 Identity, platform, and operating model

LigaChem Biosciences is identified in recent reporting as a South Korean KOSDAQ-listed biotechnology company (141080), with its headquarters reported in Daejeon. The assigned evidence describes a clinical-stage business organized around antibody-drug conjugate (ADC) discovery, platform licensing, and a growing option to advance selected assets itself. ChosunBiz describes a shift away from relying only on early licensing toward internal antibody design and later-stage development; a separate financing report says licensing remains alongside that approach. These are complementary choices, not evidence that late-stage trials have already generated commercial revenue. The available sources do not establish a founding date, a complete corporate profile, or a current audited scale baseline, so those items remain explicit diligence gaps rather than inferred facts.[CO001, CO002, CO003]

1.2 Partnered pipeline and dated execution

Public updates show a mixture of licensed and company-directed programs. In June 2026, a securities analyst described LCB84 as being in a global Phase 1 trial and discussed a possible later option exercise by Janssen; that payment was prospective, not cash already received. At the July 2026 R&D event, the company reported clinical progress across partner assets, including LCB97 with Ono, SOT106 with SOTIO, IKS014 with Iksuda, and CS5001 with CStone. Separate reports describe LigaChem taking sole development decision rights for LNCB74 after NextCure changed its oncology strategy, and reporting first-patient dosing for in-house LCB02A in October. These milestones establish activity, not clinical efficacy or approval; the timeline distinguishes completed events from forecasts and reported company plans.[CO004, CO005, CO006, CO007, CO008, CO016]

1.3 Financing, cash visibility, and scale gaps

June 2026 reporting described a KRW 500 billion financing comprising convertible preferred shares and convertible bonds, with the Korea Development Bank and Pan Orion among the named participants. That financing is not interchangeable with cash currently available: a separate report placed cash, time deposits, and repurchase agreements at approximately KRW 443.7 billion at the end of the first quarter of 2026, before the later financing and subsequent uses. The two reports translate the KRW 500 billion financing into different U.S.-dollar amounts, so the KRW denomination is the reliable common measure here. No assigned source provides a current valuation, revenue or run-rate, total historical capital raised, employee count, customer count, or a post-financing runway calculation. Those unsupported metrics are left unquantified.[CO009, CO010, CO011, CO012]

1.4 Leadership coverage and execution risk

The available reporting identifies Park Se-jin as CEO in August and October 2026 coverage and identifies Kim Yong-ju as chair at the July 2026 R&D event; an earlier company announcement described Kim as CEO. This time-stamped evidence is not a complete executive or board roster and does not establish founder backgrounds, board composition, succession arrangements, or key-person dependence. The company has publicly described ambitious pipeline expansion and an increased willingness to fund later-stage trials, making capital allocation and clinical execution important diligence questions. An independent blog author also questioned whether Orion can produce tangible biotech synergies and whether its capital-allocation culture fits high-risk drug development. That is a reported concern, not proof of failed integration; governance records and asset-level budgets are needed to resolve it.[CO013, CO014, CO015]

2.1 Market boundary and value capture

The usable market boundary is commercial ADC medicine revenue, not every dollar associated with developing an ADC. Market-research pages segment the category by application, product, technology, payload, geography, and distribution channel, while The Business Research Company explicitly describes factory-gate values; those conventions should not be silently combined with downstream hospital spending. Licensing upfronts, development milestones, and royalties are a separate value-capture path for a platform developer, and dedicated ADC manufacturing is an adjacent supply market rather than a directly comparable drug-sales total (CM001, CM012, CM016). Seoul Economic Daily reported a move from licensing candidates toward more direct late-stage trials and commercialization, changing who would bear clinical and commercialization costs but not the definition of worldwide ADC drug sales (CM012). A separate reported rights change illustrates why asset-level scope and economics vary: LigaChem secured sole rights over LNCB74 after its partner shifted direction, while retaining milestone and royalty obligations (CM014, CM015). The boundary table therefore keeps therapeutic sales, licensing economics, manufacturing, and substitutes separate. None of the supplied market previews identifies an auditable LigaChem-specific market share.[CM001, CM012, CM014, CM015, CM016]

2.2 Published market estimates are not a single TAM

Three publisher lenses establish a useful scale range but not a consensus forecast. Grand View Research reports a 2025 global market of $14.5 billion and projects $32.1 billion by 2033, with an 11.5% CAGR for 2026–2033; The Business Research Company reports $16.53 billion in 2025 and $46.95 billion in 2030, with a 23.3% CAGR for 2026–2030; Research and Markets previews $13.77 billion of incremental growth over 2025–2030 at a 15.7% CAGR, without disclosing base or ending market values in the preview (CM002–CM004). These estimates retain their own periods and definitions: no average is justified, and the incremental-growth figure is not a market-size starting point. As a directional composition lens, Grand View reports 2025 shares across applications, products, technologies, payloads, channels, and regions; those shares describe separate cuts of the same market and must not be summed (CM005–CM008). The bar chart displays selected shares as separate indicators, not as nested layers or a LigaChem SAM.[CM002, CM003, CM004, CM005, CM006, CM007, CM008]

2.3 Segments, buyers, and adoption path

The market is segmented by the therapy's commercial indication and product attributes, but the assigned evidence does not show who holds each treatment budget or how net prices are negotiated. Grand View identifies hospital pharmacy as the largest 2025 distribution channel at 52.8%; this is a channel share, not proof that hospitals are the ultimate payer or procurement decision-maker (CM008). The buyer map distinguishes commercial ADC distribution from upstream licensing and clinical development and labels budget ownership as unavailable where the sources do not specify it. On LigaChem's supply side, Seoul Economic Daily reported a 2026 ₩500 billion investment package alongside a strategic shift toward directly pursuing late-stage trials and commercialization; this is reported financing and strategy, not evidence of commercial product sales (CM012). Chosun reported first dosing in the company's in-house LCB02A global Phase 1/2 study, and Patsnap Synapse separately lists LCB-02A at Phase 1/2 (CM013). These development milestones show a path toward possible adoption, not approval, uptake, reimbursement, or realized demand.[CM008, CM011, CM012, CM013]

2.4 Adoption drivers, constraints, and unresolved sizing

Publisher summaries identify cancer burden, precision-oncology adoption, biomarker-driven targets, and linker/payload innovation as demand drivers; they also flag high development and manufacturing costs, supply-chain complexity, off-target safety concerns, and regulatory requirements as constraints (CM009, CM010). These industry-level observations do not establish that LigaChem's platform will win a specific target or that broad market growth will convert into its revenue. The reported LNCB74 arrangement shows that rights, cost exposure, and potential proceeds are contract-specific: LigaChem gained sole decision-making authority after its partner changed direction, while milestone and royalty payments remain tied to commercialization (CM014, CM015). This case does not quantify market demand or a company-wide opportunity. The estimate dispersion, missing payer economics, and lack of asset-level addressable-spend data mean SAM and SOM remain unquantified. Diligence should obtain report-level definitions and underlying models, indication-specific treatment and reimbursement data, and partner contracts showing rights, milestones, royalties, and commercialization responsibilities before translating the global drug-sales market into LigaChem value.[CM009, CM010, CM011, CM014, CM015]

3.1 A crowded ADC field makes evidence stage the key comparison

The relevant competitive set is not limited to other ADC platform companies: it includes approved target-specific therapies, partnered pipeline assets, and the standard-of-care regimen patients receive before or after progression. Grand View Research estimates the global ADC market at USD 14.5 billion in 2025 and forecasts USD 32.1 billion by 2033 at an 11.5% CAGR from 2026 to 2033; its report also assigns Enhertu a 27.9% share of 2025 product revenue (CP010, CP011). ResearchandMarkets lists a different forecast horizon and growth rate, so the estimates should not be combined as if they were a single consensus (CP014). These are third-party market estimates, not LigaChem revenue or an addressable market calculation. The operational test is whether LigaChem's clinical candidates convert mechanism and preclinical differentiation into patient-level benefit, while established products retain clinical adoption and commercial reach. [CP010, CP011, CP014]

3.2 LCB02A enters an early evidence slot against an established first-line option

LCB02A is a CLDN18.2-directed ADC in a global Phase 1/2 study, with LigaChem reporting preclinical activity and a trial design that includes patients previously treated with CLDN18.2-directed therapy (CP001, CP002, CP003). The immediate comparator is not another platform claim: IRpharm describes Astellas' zolbetuximab (Vyloy) as an established first-line regimen and reports no approved alternative after progression (CP004). That creates a plausible post-progression opening, but it does not show LCB02A will be safe or effective in that setting. In HER2, Iksuda's Phase 1b LCB14/IKS014 and marketed Enhertu occupy different evidence and commercial positions; Edaily reports Pfizer acquired global rights to RemeGen's disitamab vedotin for a stated total deal value of USD 4.3 billion (CP005, CP006, CP007). The ordinal figure summarizes these stage differences; it is not a clinical ranking or a measured market-share comparison. [CP001, CP002, CP003, CP004, CP005, CP006, CP007, CP011]

3.3 Platform differentiation is promising but partner and execution dependencies remain

LigaChem's ConjuALL platform is described by the company as a next-generation ADC platform, and IRpharm reports that it was used to construct LCB02A (CP001). The same article reports a homogeneous DAR 4, exatecan-based payload, and CLDN18.2 selectivity, but these are preclinical and company-presented findings rather than independent head-to-head evidence (CP003). For partnered programs, Edaily reports that Iksuda is developing LCB14/IKS014 and CStone is advancing the ROR1 ADC CS5001/LCB71; The Pharma Letter describes CStone's exclusive global rights outside South Korea (CP005, CP008, CP013). LigaChem also regained sole decision authority over LNCB74 after NextCure shifted away from oncology, taking on future milestone and royalty obligations (CP015). Partner access expands reach, but partner strategy changes can return development responsibility and cost exposure to LigaChem. Patent enforceability, manufacturing consistency, supply access, and partner-level clinical execution are not established by this evidence set. [CP001, CP003, CP005, CP008, CP013, CP015, CP016]

3.4 Pricing and independent comparative proof remain diligence gaps

The assigned sources do not provide comparable per-dose prices, realized discounts, payer terms, or customer switching data for the listed therapies. The reported LCB97 licensing ceiling and milestone estimate are contract economics, not product pricing, recognized revenue, or cash available for development (CP009, CP012). Nor does the company-issued comparison of CS5001 with other ROR1 ADCs substitute for a prespecified independent benchmark or head-to-head clinical result (CP008). The competitive thesis therefore remains conditional: clinical differentiation must be confirmed in patients, partner execution must continue, and the platform's freedom-to-operate and scalable supply position require separate diligence. Internal-build alternatives and likely new entrants are not sufficiently enumerated in the available sources to rank. [CP008, CP009, CP012, CP015, CP016]

3.5 Exhibits

4.1 Licensing monetizes pipeline progress, not recurring software revenue

LigaChem describes a clinical-stage therapeutics business spanning ADCs, small molecules, and worldwide partnerships; the public sources reviewed do not disclose a recurring subscription or unit-based pricing schedule. Available deal reporting instead supports a mix of upfront consideration, development and regulatory milestones, and post-launch royalties, with timing contingent on partner and clinical progress. For LCB84, coverage reports a $100 million upfront payment within a deal valued at up to $1.7 billion, while the additional $200 million discussed by an analyst depended on a future option exercise. For LCB97, the trial-start milestone was confidential and a news outlet estimated its minimum from prior-year revenue. These deal ceilings and estimates are not recognized revenue or guaranteed cash receipts. The first table separates the evidenced streams from terms and operating metrics that remain private.[CI008, CI005, CI009, CI010, CI015]

4.2 Reported losses make revenue quality and cash conversion central

BizHankook reported 2025 consolidated revenue of KRW 141.6 billion, operating loss of KRW 106.5 billion, and net loss of KRW 91.6 billion; Seoul Economic Daily gave the underlying revenue figure as KRW 141.55307 billion. The same BizHankook report put first-quarter 2026 revenue at KRW 35.9 billion, operating loss at KRW 37.4 billion, and net loss at KRW 33.3 billion. These are reported accounting results, not a cash-burn calculation. The source also described cash and cash equivalents falling from KRW 98.6 billion at 2025 year-end to KRW 63.5 billion at first-quarter end, and KRW 46.4 billion of first-quarter outsourcing costs related to new-drug R&D. Neither a single-quarter loss nor one cost line establishes total operating cash use, asset-level cost, or runway.[CI001, CI002, CI003, CI004, CI005, CI006]

4.3 New financing expands the stated development envelope, not verified runway

June coverage described a KRW 500 billion financing package, but differs in how it characterizes completion and the instrument and investor mix. WOWTALE called it a raised direct investment and reported KRW 170 billion of convertible bonds plus KRW 330 billion of convertible preferred shares; BizHankook described a KRW 500 billion fundraising effort and a different allocation among policy funds, the controlling shareholder, development bank, and institutions. The stated use was R&D and clinical development, including building capacity for Phase 2 and Phase 3 trials. This is financing raised or arranged, not proof of cash currently available: conversion terms, timing of proceeds, restrictions, current balance, and planned asset-level commitments need reconciliation. Independent reporting also described late-stage trials and independent development as increasing funding pressure; no precise cash runway can be inferred from the disclosed accounting losses.[CI004, CI005, CI006, CI005, CI011, CI012]

4.4 Underwriting remains blocked by private contract and cost data

The public record is useful for identifying the revenue mechanism and selected milestone events, but not for estimating repeatability or contribution margin. Ono's LCB97 payment amount was confidential, with the reported minimum an outside estimate; the LCB84 deal ceiling includes future contingencies, and reported royalties begin only after launch. LigaChem's transfer of sole LNCB74 decision-making rights also leaves it responsible for development choices and contingent milestone and royalty payments to NextCure. Meanwhile, the company is advancing an in-house clinical candidate, which adds a distinct cost-bearing path. There is no cited product-level revenue mix, realized royalty rate, gross margin, program budget, working-capital schedule, or reconciled post-financing cash-and-burn bridge. The diligence priority is to obtain partner-level revenue and recognition schedules, asset-level spend, and a current treasury forecast before underwriting runway or margin expansion.[CI007, CI008, CI005, CI009, CI010, CI011, CI012, CI013, CI014]

4.5 Exhibits

5.1 Platform and reported molecular design

LigaChem presents ConjuALL as a next-generation antibody-drug-conjugate platform and claims a higher therapeutic index, but its public technology page does not provide comparative data. TechTimes describes LNCB74 as a B7-H4-directed, MMAE-payload ADC using site-specific light-chain conjugation, a glucuronidase-cleavable linker, and an engineered DAR4 design; those details are reported design attributes, not independently verified clinical advantages. The architecture figure keeps the distinction visible: antigen recognition and controlled payload delivery are hypotheses to test in patients, not evidence of improved outcomes. The article says LNCB74 is in Phase 1, and the reported mechanism remains preclinical in this evidence set. (CE001, CE002, CE003, CE004)[CE001, CE002, CE003, CE004]

5.2 Named assets and clinical workflow

The disclosed portfolio spans targets and partner models rather than a single product workflow. LNCB74 is a Phase 1 B7-H4 program; LCB84 is a TROP2 ADC licensed to Johnson & Johnson and reported in global Phase 1; LCB97 is a licensed L1CAM ADC reported to have entered global Phase 1; LCB02A is a CLDN18.2 ADC whose registry describes a Phase 1/2 study, with first-patient dosing reported on October 16, 2026. The registry lists an estimated enrollment of 191, not completed enrollment or a result. These stages show clinical activity, but the evidence does not establish response rates, durability, dose selection, or commercial readiness. Target-positive eligibility, trial progression, and any treatment benefit must therefore stay separate. (CE004, CE005, CE006, CE008, CE009, CE010, CE011, CE012)[CE004, CE005, CE006, CE008, CE009, CE010, CE011, CE012]

5.3 Partnering and manufacturing dependencies

The product model combines internal discovery with external development and manufacturing relationships. LigaChem obtained sole decision-making authority over LNCB74 after NextCure exited co-development, while NextCure retains potential milestone and royalty economics. A Samsung Biologics release says it will support a series of LigaChem ADC programs at its dedicated ADC facility; the announcement describes a 500-liter reactor and services from late discovery through development and conjugation, but does not name which programs receive capacity. CStone holds global development and commercialization rights to CS5001 outside Korea, according to The Pharma Letter. A 2026 report also describes eight global trials, including one Phase 3 breast-cancer trial, as a portfolio snapshot. Capacity allocation, process validation, lot quality, supply reliability, and the identity and status of that Phase 3 asset remain diligence items. (CE005, CE013, CE014, CE015, CE016)[CE005, CE013, CE014, CE015, CE016]

5.4 What the evidence does not establish

The strongest public evidence is about candidate descriptions, trial design, and announced relationships—not clinical performance. The ClinicalTrials.gov record for LCB02A lists no study results and records no data monitoring committee; this is registry metadata, not proof that no other safety oversight exists. TechTimes itself notes that LNCB74's proposed linker and payload advantages still need to be demonstrated in patients. No assigned source provides comparative human outcomes, validated CMC release metrics, facility allocation or uptime, or freedom-to-operate analysis for ConjuALL. Nor does the assigned evidence establish a public developer surface or a practitioner-community proxy for this clinical biotech product. These are material gaps for assessing repeatable product performance, safety, and execution risk. (CE002, CE003, CE012, CE014, CE016)[CE002, CE003, CE012, CE014, CE016]

6.1 Partner-led model and customer segments

The disclosed commercial surface is predominantly business-to-business partnering rather than a directly served end-user base. The sources identify global licensees, an antibody technology provider, a co-development counterparty, and a contract-manufacturing collaboration; those roles have different economics and should not be counted as interchangeable customers. J&J and Ono are associated with licensed assets, while NovaRock supplied antibody technology and Samsung Biologics was described as a manufacturing collaborator. The public materials reviewed do not reconcile counterparties to recognized revenue, contract duration, or active commercial products. A news report also described Orion's strategic investment and said Orion had no further investment planned at that time; this is shareholder support, not customer demand. (CU001, CU003, CU005, CU007, CU012, CU014, CU015)[CU001, CU003, CU005, CU007, CU012, CU014, CU015]

6.2 Adoption is visible as pipeline progress, not recurring use

The strongest adoption indicators in this evidence set are partner-led clinical progression and a milestone linked to patient dosing. ClinicalTrials.gov listed the LNCB74 study as recruiting in Phase 1 at its August 2026 update, with estimated enrollment of 145; the registry names NextCure as sponsor and LigaChem as collaborator. Separately, a July report said an Ono milestone was triggered by first-patient dosing of LCB97, but the payment amount was confidential and the article's KRW 14.1 billion minimum was an estimate. These are meaningful development and contract-conversion signals, yet neither confirms launch, realized royalties, repeat purchasing, or patient outcomes. The July plan for LCB02A to enter Phase 1 in Q3 2026 remains a dated plan in the available evidence, not a verified enrollment event. (CU006, CU008, CU009, CU010, CU011, CU013, CU015)[CU006, CU008, CU009, CU010, CU011, CU013, CU015]

6.3 Named partner proof and durability gaps

Named relationships provide proof of counterparties and contractual activity, but the evidence is uneven in independence and maturity. The NovaRock antibody agreements appear in two company-announcement reports, so those articles are not independent confirmation of the same transaction; their target identities and financial terms were withheld. The LNCB74 relationship has stronger external triangulation because a public trial record complements reporting on the rights transition. The reviewed sources do not disclose an active customer count, partner-level revenue concentration, renewals, retention, or repeat-use rates. Those gaps prevent a reliable durability or customer-concentration estimate; the available named-deal sample is not an exhaustive customer list. (CU001, CU002, CU010, CU011, CU012, CU016)[CU001, CU002, CU010, CU011, CU012, CU016]

7.1 Contractual, legal, and regulatory exposure

The strongest evidenced legal/contractual risk is counterparty continuity rather than a reported dispute. After NextCure shifted its business direction following a merger, the LNCB74 collaboration terms changed and LigaChem obtained sole decision authority; the revised economics include milestone and royalty obligations to NextCure. This demonstrates that partner strategy can change who controls development and bears cost, but the available report does not establish that the change involved a breach or litigation. The assigned sources do not provide a current patent-office landscape, freedom-to-operate opinion, regulator inspection history, or complete trial authorization records. These are evidence gaps, not evidence that a dispute, compliance failure, or safety event exists. Obtain counsel-reviewed contract and patent diligence and regulator records before treating these exposures as cleared.[CR003, CR012, CR014]

7.2 Clinical execution, quality, and operational risk

The portfolio remains exposed to the ordinary but consequential uncertainty of clinical development: early-stage progress does not establish safety, efficacy, approval, or commercial supply. A third-party pipeline database lists multiple ADC programs and identifies LCB-84 as Phase 1/2, while the company profile describes LigaChem as clinical-stage. The source pool contains no trial-level adverse-event, enrollment, CMC validation, manufacturing-capacity, or product-quality records sufficient to assess those controls. Treat trial failure or delay as a high-impact exposure, but do not infer a current failure or quality defect. Diligence should track protocol milestones, enrollment and safety updates, comparability and release metrics, qualified manufacturing capacity, and contingency plans; a material safety signal, repeated timeline reset, or unresolved CMC deficiency should pause incremental risk-taking.[CR001, CR006, CR016]

7.3 Financial resilience and capital needs

Cash and earnings indicators are period-sensitive and should not be collapsed into a single runway estimate. Yahoo Finance's late-October snapshot reports KRW 383.86 billion of cash, 0.59% total debt/equity, negative TTM net income, and negative levered free cash flow. BizHanKook's earlier report instead describes cash declining from KRW 98.6 billion at 2025 year-end to KRW 63.5 billion at 2026 Q1-end, alongside Q1 operating and net losses and KRW 46.4 billion of outsourced R&D costs. Those snapshots are not necessarily contradictory: the earlier report also describes a subsequent financing effort, while the newer cash figure has a different as-of period. They do not prove current distress or a durable runway. Reconcile audited cash, restricted balances, financing proceeds, asset-level spend, and quarterly burn before relying on any runway claim.[CR004, CR005, CR008, CR009, CR010, CR015]

7.4 Partner dependence and thesis-break monitoring

Licensing can shift late-stage trial and commercialization costs to partners, but it also leaves LigaChem dependent on counterparties' priorities, execution, and contractual options. The LNCB74 change illustrates this control risk; the LCB97 report provides a separate example of a partner-triggered milestone whose exact amount was confidential and whose payment was expected after invoicing. The source pool does not quantify partner-level revenue concentration, milestone timing by program, or royalty-conversion history, so the degree of portfolio diversification remains unknown despite multiple programs. Track partner trial progression, option exercises, termination notices, milestone receipts, and concentration by counterparty. A partner withdrawal from a lead program, repeated deferral of clinical milestones, or evidence that one counterparty dominates expected receipts should trigger a downside re-underwrite rather than be offset by unverified pipeline breadth.[CR007, CR011, CR013, CR014]

7.5 Exhibits

8.1 A price-sensitive research-more call

LigaChem's licensing history and clinical progress create a credible platform thesis, but they do not convert headline deal values into current revenue or cash. A Seoul Economic Daily report cited a $1.7 billion total LCB84/J&J deal and $100 million upfront payment, while describing a further $200 million as conditional on J&J exercising an option; those contingent amounts are not realized receipts (CV002, CV003). The same retained pool reports losses and declining cash, as well as a KRW 500 billion financing transaction (CV008-CV011). Gosset's preview lists market capitalization, enterprise value, and total revenue, but does not date or define the financial periods for those figures (CV013). In the absence of a date-matched share count, current price, cash/debt bridge, and risk-adjusted revenue model, no responsible entry multiple, target return, or numeric bull/base/bear range can be calculated. The practical call is research-more, with a high risk rating and no numeric target until those inputs are reconciled.[CV002, CV003, CV008, CV009, CV011, CV013]

8.2 Partner economics and clinical proof are real but uneven

LigaChem describes itself as a clinical-stage company focused on ADC and immuno-oncology medicines, and the retained evidence includes both an out-licensed asset and internally advanced programs (CV001, CV002, CV004). The LCB84 agreement supplies strategic validation and an upfront payment, but the reported total deal value includes contingent economics; the analyst's additional $200 million is explicitly conditional rather than booked cash or guaranteed revenue (CV002, CV003). Separately, after NextCure's strategic pivot, LigaChem assumed sole development, manufacturing, and commercialization authority for LNCB74, while accepting future milestone and royalty obligations (CV005, CV006). That control can improve strategic optionality while also shifting clinical execution and funding burden to LigaChem. A PharmaLetter company profile documents an earlier CS5001 licensing arrangement, but it is a dated profile and not evidence of current royalty conversion or repeatable economics (CV014). The thesis strengthens only when trial outcomes and partner cash conversion—not deal headlines alone—are observable.[CV001, CV002, CV003, CV004, CV005, CV006, CV014]

8.3 Financing extends capacity but does not settle runway

BizHankook reported KRW 141.6 billion of 2025 consolidated revenue, alongside a KRW 106.5 billion operating loss and KRW 91.6 billion net loss; it also reported cash and cash equivalents falling from KRW 98.6 billion at year-end 2025 to KRW 63.5 billion at the end of the first quarter of 2026, with KRW 46.4 billion of first-quarter outsourced research and development costs (CV007-CV010). These are distinct accounting and cash measures, not a single burn-rate calculation. A separate report describes KRW 500 billion in convertible bonds and convertible preferred shares, while another attributes an approximately KRW 1 trillion development-funds figure to an Orion official (CV011, CV012). The latter estimate combines reported funding and purported existing cash, but its date, restrictions, and reconciliation to the quarter-end cash figure are not established in the retained text. Convertible securities can also dilute equity or create preference overhang; issue-level terms, fully diluted shares, and current available cash remain diligence items, not assumed funding capacity.[CV007, CV008, CV009, CV010, CV011, CV012]

8.4 Scenarios remain directional until valuation inputs are verified

The bull case requires partner progression on LCB84, demonstrated safety and efficacy in clinical programs, and cash receipts that convert contracted economics into reported revenue; a first dose in LCB02A's global Phase 1/2 trial is execution evidence, not efficacy evidence (CV002-CV004). The base case should assume milestone timing remains uncertain and that internal development continues to consume capital. The bear case is a clinical delay or failure combined with continuing losses, financing needs, or dilution; the LNCB74 rights transition also leaves LigaChem responsible for future program obligations (CV005, CV006, CV008-CV012). The available evidence does not establish probability-weighted cash flows, comparable-company assumptions, or a date-matched fully diluted valuation. Accordingly, the scenario table gives qualitative probability signals and explicitly withholds numeric value ranges rather than manufacturing precision. A refreshed price and capitalization bridge, financing terms, partner receipts, and trial readouts are the decision gates for moving from research-more to a return-based recommendation.[CV002, CV003, CV004, CV005, CV006, CV008, CV011, CV013]

8.5 Exhibits